Stock comparison
CeriBell
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CBLL
CeriBell
Market cap
$712.18M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CBLL | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 75B | IDXX |
| Benjamin Graham | 58D | 80A | IDXX |
| Philip Fisher | 58C | 75B | IDXX |
| Peter Lynch | 48D | 71B | IDXX |
| Joel Greenblatt | 4F | 83C | IDXX |
| Charlie Munger | 38D | 87A | IDXX |
| Terry Smith | 41D | 84A | IDXX |
Side-by-side metrics
| Metric | CBLL | IDXX |
|---|---|---|
| Market cap | $712.18M | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | -39.83% | 40.66% |
| Gross margin | 87.72% | 62.05% |
| Net margin | -63.51% | 24.63% |
| Revenue CAGR 5y | 50.9% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CBLL leads on
- EV/EBIT-vs 31.6x+133%
- P/E (TTM)-vs 39.0x+127%
- Revenue CAGR 5y50.9%vs 7.56%+85%
- Debt / Equity0.2xvs 0.7x+77%
IDXX leads on
- ROIC (TTM)40.66%vs -39.83%+198%
- Net margin24.63%vs -63.51%+139%
- Market cap$44.12Bvs $712.18M+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.